COUR Pharma closes $50 million Series B led by Lumira Ventures, Roche Venture Fund

  • COUR Pharma, a clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases, closed a USD 50 million Series B round.
  • The financing was led by Lumira Capital Investment Management Inc’s Lumira Ventures alongside Roche Venture Fund, with new investment from Sanofi.
  • Proceeds will fund clinical advancement of CNP-103, a nanoparticle-based investigational therapy in a Phase 2 trial for recent-onset type 1 diabetes.
  • COUR is also seeking partners to develop CNP-104 in primary biliary cholangitis, with CNP-106 in myasthenia gravis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lumira Capital Investment Management Inc published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.